Clinical Trial Update: Phase 2 Study of AMG 386 (20060439) in Combination With Cisplatin & Capecitabine in Subjects With Metastatic Gastric, Gastroesophageal Junction, or Distal Esophageal Adenocarcinoma [Phase 2]

View source ↗

Summary

This Phase 2 trial evaluated trebananib (AMG 386) in combination with cisplatin and capecitabine for metastatic gastric, gastroesophageal junction, or distal es…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Esophageal Adenocarcinoma
• Gastric Cancer
• Gastroesophageal Junction Adenocarcinoma

Drugs mentioned

• AMG-386 (trebananib)
• CISPLATIN (cisplatin)
• Capecitabine (capecitabine)

Snippet

Sponsor: Amgen | Conditions: Gastrointestinal Cancer | Phase 2 | Status: COMPLETED